期刊
ALLERGY
卷 64, 期 12, 页码 1737-1745出版社
WILEY
DOI: 10.1111/j.1398-9995.2009.02232.x
关键词
Consort; Ga2len; specific immunotherapy; randomized controlled trial
资金
- GA2LEN
- Medical Research Council [G9805965] Funding Source: researchfish
- MRC [G9805965] Funding Source: UKRI
The methodology of randomized clinical trials is essential for the critical assessment and registration of therapeutic interventions. The CONSORT (Consolidated Standards of Reporting Trials) statement was developed to alleviate the problems arising from the inadequate reporting of randomized controlled trials. The present article reflects on the items that we believe should be included in the CONSORT checklist in the context of conducting and reporting trials in allergen-specific immunotherapy. Only randomized, blinded (in particular blinding of patients, health care providers, and outcome assessors), placebo-controlled Phase III studies in this article. Our analysis focuses on the definition of patients' inclusion and exclusion criteria, allergen standardization, primary, secondary and exploratory outcomes, reporting of adverse events and analysis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据